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Abstract
Background: Synaptic dysfunction contributes to cognitive impairment in Alzheimer’s disease and may be
countered by increased intake of nutrients that target brain phospholipid metabolism. In this study, we explored
whether the medical food Souvenaid affects brain phospholipid metabolism in patients with Alzheimer’s disease.
Methods: Thirty-four drug-naive patients with mild Alzheimer’s disease (Mini Mental State Examination score ≥20) were
enrolled in this exploratory, double-blind, randomized controlled study. Before and after 4-week intervention with
Souvenaid or an isocaloric control product, phosphorus and proton magnetic resonance spectroscopy (MRS) was
performed to assess surrogate measures of phospholipid synthesis and breakdown (phosphomonoesters [PME] and
phosphodiesters [PDEs]), neural integrity (N-acetyl aspartate), gliosis (myo-inositol), and choline metabolism (choline-
containing compounds [tCho]). The main outcome parameters were PME and PDE signal intensities and the PME/PDE ratio.
Results: MRS data from 33 patients (60–86 years old; 42% males; Souvenaid arm n= 16; control arm n= 17) were analyzed.
PME/PDE and tCho were higher after 4 weeks of Souvenaid compared with control (PME/PDE least squares [LS] mean
difference [95% CI] 0.18 [0.06–0.30], p= 0.005; tCho LS mean difference [95% CI] 0.01 [0.00–0.02], p= 0.019). No significant
differences were observed in the other MRS outcome parameters.
Conclusions: MRS reveals that Souvenaid affects brain phospholipid metabolism in mild Alzheimer’s disease, in line with
findings in preclinical studies.
Trial registration: Netherlands Trial Register, NTR3346. Registered on 13 March 2012.
Keywords: Nutrition, Phospholipid metabolism, Magnetic resonance spectroscopy, 31P-MRS, 1H-MRS, Medical food,
Alzheimer’s disease, Dementia, Souvenaid, Fortasyn Connect
Background
Synaptic dysfunction is a major contributing factor to cog-
nitive impairment in Alzheimer’s disease (AD) [1, 2] and
may be caused by deficits in neuronal membrane compos-
ition and function [3, 4]. Because the neuronal membrane
is composed mainly of phospholipids [5], interventions that
target brain phospholipid metabolism may affect cognitive
function in AD.
The most abundant phospholipids in the neuronal
membrane are phosphatidylethanolamine (PE) and
phosphatidylcholine (PC) [4, 5]. They are formed in the
Kennedy cycle, wherein phosphomonoesters (PMEs) are
converted to phospholipids that can then be incorporated
into neuronal membranes [6]. The breakdown of these
phospholipids releases phosphodiesters (PDEs), which can
either be used for resynthesis or broken down further [7].
The synthesis of brain phospholipids is influenced by the
availability of specific nutrients to the brain, consisting of
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rate-limiting phospholipid precursors [8, 9]. This is affected
not only by nutritional intake but also by the intake of
cofactors that influence precursor uptake and metabolism.
Increasing the availability of several precursors proved to
have a synergistic effect on phospholipid formation as well as
on dendritic spine density [9–12]. Furthermore, circulating
levels of most of these nutrients (precursors and cofactors) as
well as brain choline levels are lower in patients with AD
[13–15], thus lowering precursor availability. The specific
multinutrient combination Fortasyn® Connect (FC) in the
medical food Souvenaid® (Nutricia Advanced Medical
Nutrition, Utrecht, The Netherlands) contains precursors
and cofactors in the phospholipid synthesis pathway (docosa-
hexaenoic acid [DHA]; eicosapentaenoic acid [EPA]; uridine
monophosphate [UMP]; choline; phospholipids; selenium;
folic acid; and vitamins B6, B12, C, and E), and it has been
formulated to promote neuronal membrane (phospholipid)
formation and function in AD [8]. Previous studies in animal
models of AD and aging have shown that long-term supple-
mentation with FC positively affects exploratory behavior
and memory [16, 17], in addition to enhancing phospholipid
synthesis and improving cholinergic transmission [18]. This
indicates that supporting synaptic function by increasing
phospholipid formation is a promising strategy to improve
cognition or reduce cognitive decline.
Randomized controlled trials with patients with AD dem-
onstrated improvement in memory performance in those
with mild AD over 12–24 weeks of intervention with this
specific multinutrient combination [19, 20] as well as altered
functional connectivity and preserved brain network
organization [20, 21]. However, the physiological underpin-
nings in humans remain to be further elucidated. The
present study was designed to provide more insight into the
hypothesized underlying mechanisms of FC (i.e., promoting
neuronal membrane [phospholipid] formation and function)
in humans.
Neither synapse number nor phospholipid membrane
composition can be assessed directly in vivo, but phos-
phorus magnetic resonance spectroscopy (31P-MRS) allows
for the noninvasive investigation of phospholipid building
blocks and breakdown products (i.e., PME and PDE, re-
spectively) [22]. In addition, using proton (1H) MRS, brain
metabolites related to neural integrity (N-acetylaspartate
[NAA]), gliosis (myo-inositol [mI]), choline metabolism
(total choline [tCho]), and energy metabolism (total creatine
[tCr]) can be assessed as well [22, 23]. Hence, in the present
study, we explored whether the medical food Souvenaid af-
fects brain phospholipid metabolism and neural integrity in
patients with mild AD using 31P-MRS and 1H-MRS.
Methods
Subjects and design
The MRS AD study was a 4-week, randomized, controlled,
double-blind, single-center trial with patients with mild
AD. Significant effects of FC on memory performance were
reported in this population previously [19, 20]. In the
present study, we explored whether FC affects brain
phospholipid metabolism in patients with mild AD. All
visits took place between October 2012 and February 2015
at the Radboud University Medical Center (Nijmegen, The
Netherlands). AD drug-naive patients aged ≥50 years with
a diagnosis of probable or possible AD (according to the re-
vised 2011 criteria of the National Institute of Neurological
and Communicative Disorders and Stroke and Alzheimer’s
Disease and Related Disorders Association [24]) with
evidence of the pathophysiological process (i.e., from struc-
tural magnetic resonance imaging [MRI] or cerebrospinal
fluid [CSF] biomarker assays), a Mini Mental State Examin-
ation (MMSE) score ≥20, and a Geriatric Depression Scale
(GDS) score ≤6 (of 15) were recruited from the hospital’s
memory clinic or by referral from regional hospitals. All
subjects were drug-naive for AD medication (cholinesterase
inhibitors and N-methyl-D-aspartate antagonists) and were
free of neurological or psychiatric disorders (other than de-
mentia). To increase subject recruitment, eligibility criteria
were extended during the study to include patients who were
off AD medication for at least 3 months prior to the study,
but no additional subjects were recruited who did not meet
the original criteria. Subjects did not consume oily fish more
than twice per week or use nutritional supplements contain-
ing DHA, EPA within 2 months prior to baseline, or nutri-
tional supplements containing >200% of the recommended
daily allowance of vitamins B6 (2.8 mg), B12 (5 μg), C (160
mg), E (24 mg), or folic acid (0.4 mg) within 1 month prior
to baseline. Use of anticholinergic or antipsychotic medica-
tion and of other medical foods or investigational products
was also prohibited within 1 month prior to baseline, as well
as changes in dose of lipid-lowering medication, antihyper-
tensives, and/or antidepressants. All subjects were screened
for MRI contraindications before inclusion in the study.
Written informed consent was obtained from all patients and
their informal caregivers. The local ethics committee
reviewed and approved the protocol. The study was con-
ducted in accordance with the Declaration of Helsinki and is
registered in the Netherlands Trial Register (NTR3346).
Medical history, medication and nutritional supplement
use, MMSE score, GDS score, date of birth, sex, ethnicity,
smoking habits, alcohol consumption, and family history of
AD were recorded for all subjects at the first (screening)
visit. Eligible subjects were randomly allocated to receive ei-
ther the test product (i.e., Souvenaid containing the specific
nutrient combination FC) or an isocaloric control product
once daily as a drink for a double-blind period of 4 weeks
(1:1 randomization, stratified on the basis of sex). The test
product contained DHA; EPA; phospholipids; choline;
UMP; selenium; folic acid; and vitamins B6, B12, C, and E
(Table 1). On the basis of previous publications in which
31P-MRS brain metabolites in humans were already affected
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after 1-week administration of uridine [25] and 6-week ad-
ministration of citicoline [26], it was expected that an inter-
vention period of 4 weeks was sufficient to observe an
effect of the test product on 31P-MRS brain metabolites.
Numbered and sealed randomization envelops (contain-
ing one of four codes, two representing the test group and
two the control group) were generated at Nutricia Research
by the clinical studies supplies manager and opened upon
randomization on-site by the investigator. All subjects and
any person involved in subject recruitment, group alloca-
tion, data acquisition and processing, or statistical analyses
were blinded to the intervention group (test or control)
until the analyses of the main outcome parameters were
completed. The study product was packaged in tetra-packs
(until 15 January 2014) or plastic bottles (from 15 January
2014 onward) and labeled with one of the four
randomization codes. With assistance from their informal
caregivers, subjects recorded intake of the product daily in
a diary, which was used to verify intake at the week 4 visit.
At baseline and after 4 weeks, venous blood samples
were taken and magnetic resonance (MR) measurements
were performed. MR measurements at week 4 took place
at least 2 h after intake of the last study product. For the
purposes of compliance and safety, a phone call was con-
ducted after 14 days of product intake. A final follow-up
call was conducted 2 weeks after the last visit. Subjects
were instructed to minimize intake of high-choline food
on the days of the baseline and week 4 visits and to keep
intake of concomitant nutritional supplements and
medication stable (unless deemed necessary by their phys-
ician) during the study. Analyses of the blood samples
were performed as reported previously [27].
MR protocol
MRI and MRS were performed on a MAGNETOM Trio
Tim System 3-T MR system (Siemens Healthcare,
Erlangen, Germany) with a dual-tuned 1H/31P volume head
coil (Rapid Biomedical, Würzburg, Germany). High-
resolution structural MR images were acquired with a T1-
weighted magnetization-prepared rapid gradient echo se-
quence (repetition time [TR] 2300 milliseconds, echo time
[TE] 3.16 milliseconds, inversion time 1100 milliseconds,
15-degree flip angle, 176 sagittal slices, slice matrix size
256 × 256, slice thickness 1 mm, voxel size 1 × 1 × 1 mm,
acquisition time [TA] 6:25 minutes).31P-MR spectra were
acquired by whole-brain 3D MR spectroscopic imaging
(MRSI; TR 2000 milliseconds, 40-degree flip angle, four av-
erages, acquisition delay 0.10 milliseconds, broadband pro-
ton decoupling applied during first half of 512-millisecond
acquisition duration, field of view (FOV) 260 × 260 × 260
mm; matrix size 10 × 10 × 10, TA 13:08 minutes). k-Space
was sampled with a weighted elliptical phase-encoding
scheme with four averages. The FOV was centered on the
midline and parallel to the line from the anterior commis-
sure to the posterior commissure. Spatial postprocessing
consisted of zero-filling to a matrix size of 16 × 16 × 16
followed by spatial Fourier transformation. The nominal
volume of the selected cubic voxels is about 17.5 cm3;
because of the spatial response function, the spectra have
contributions from a spherical area with an effective
volume of about 40 cm3 at 64% of this function [28].
1H-MR spectra of the hippocampus were acquired with a
single-slice 2D semilocalization by adiabatic selective re-
focusing (sLASER) MRSI sequence, with water suppression
enhanced through T1 effects (TR 2100 milliseconds, TE =
30 milliseconds, 90-degree excitation flip angle, six aver-
ages, FOV 120 × 160 × 10 mm, nominal voxel size 3.75 ×
5 × 10 mm), positioned parallel to the hippocampi. 1H-MR
spectra of the anterior and posterior cingulate cortices
(ACC and PCC, respectively) were acquired with a single-
voxel point resolved spectroscopy (PRESS) sequence with
chemical shift selective water suppression (TR 3000 milli-
seconds, TE 30 milliseconds, 90-degree excitation flip angle,
64 averages, voxel size 27 × 15 × 15 mm [ACC] and 20 ×
20 × 16 mm [PCC]). With each sequence, an additional MR
spectrum without water suppression was obtained (2D
sLASER: one average, PRESS: eight averages). The complete
MR protocol, including positioning of the patient, took
approximately 90 minutes. Because the 31P-MRS quantities
PME, PDE, and PME/PDE were the main outcome
measures, 31P-MRS measurements were always performed
before 1H-MRS measurements in case subjects failed to
complete the entire scanning protocol.
Table 1 Nutritional composition of the study products (amount
per daily dose of 125 ml)
Control Active
Energy 125 kcal 125 kcal
Protein 3.8 g 3.8 g
Carbohydrate 16.5 g 16.5 g
Fat 4.9 g 4.9 g
EPA 0 300 mg
DHA 0 1200 mg
Phospholipids 0 106 mg
Choline 0 400 mg
UMP 0 625 mg
Vitamin E (α-tocopherol equivalents) 0 40 mg
Vitamin C 0 80 mg
Selenium 0 60 μg
Vitamin B12 0 3 μg
Vitamin B6 0 1 mg
Folic acid 0 400 μg
EPA Eicosapentaenoic acid, DHA Docosahexaenoic acid, UMP
Uridine monophosphate
Test product is Souvenaid, containing the specific nutrient combination
Fortasyn Connect. Souvenaid and Fortasyn are registered trademarks of
Nutricia N.V
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MR data analysis
Four regions of interest (ROIs) were selected for analysis
from the 3D 31P-MRSI data: ACC, retrosplenial cortex
(RSC), and left and right hippocampi (HL and HR, respect-
ively). Voxels covering these ROIs were selected by shifting
the MRSI grid in the x, y, and z dimensions using anatom-
ical landmarks on the T1-weighted anatomical images.
From the 2D 1H-MRSI data, two voxels positioned on the
hippocampi (HL and HR, respectively) were selected for
analysis, in addition to the single-voxel data from the ACC
and PCC (Fig. 1a, c).
The Metabolite Report software package (Siemens
Healthcare) was used for postprocessing (i.e., zero-filling,
phase correction, 100-millisecond exponential filter, base-
line correction) and for automatic fitting of the 31P-MR
spectra in the time domain using prior knowledge (un-
published data Rijpma and de Graaf [29]). Eleven well-
resolved resonance peaks were fitted: the phospholipid
metabolites phosphoethanolamine (PEth), phosphocholine
(PCh), glycerophosphoethanolamine (GPEth), and glycer-
ophosphocholine (GPCh); the high-energy phosphorus
molecules phosphocreatine (PCr); adenosine triphos-
phates (ATPs) α-ATP, β-ATP, and γ-ATP; nicotinamide
adenine dinucleotide [NAD(H)] and inorganic phosphate
(Pi); and membrane-bound phospholipid (MP). The inten-
sity of each metabolite resonance was expressed as a per-
centage area of the total phosphorus signal in the
spectrum. Thus, the data are corrected for CSF content
and for differences in atrophy. PME was calculated as the
sum of PEth and PCh, PDE as the sum of GPEth and
GPCh, and total adenosine triphosphate as the sum of α-
ATP, β-ATP, and γ-ATP. In addition, the ratios PME/PDE,
PEth/GPEth, PCh/GPCh, and PCr/Pi were computed.
Intracellular pH was determined from the chemical shift
difference between the PCr and Pi resonance peaks [30].
Both a quantitative evaluation of the fitting results and a
visual quality control were performed. Quantitatively, only
fits of metabolite peaks with a Cramér-Rao lower bound
(CRLB) ≤30% were considered reliable. Qualitatively, two
spectroscopists (AR and MvdG) independently checked
the spectra by visual inspection of the original spectra and
the fitting results. If a metabolite peak was visually present
Fig. 1 Voxel selection and representative examples of 31P and 1H magnetic resonance (MR) spectra. a Voxel selection of 31P-MR spectra displayed on
sagittal (left) and coronal (right) anatomical images: anterior cingulate cortex (blue), retrosplenial cortex (yellow), left and right hippocampus (purple).
The nominal voxel size is indicated by squares, and the approximation of the effective spherical voxel size is indicated by circles. b Representative
31P-MR spectrum from the retrosplenial cortex. Zero-filling to 4096 data points and an 8-Hz Gaussian filter were applied. c Sagittal (left) and transversal
(right) anatomical images showing single-voxel volumes of 1H-MR spectra in anterior cingulate cortex (blue), posterior cingulate cortex (yellow), and
voxel selection of left and right hippocampi (purple). d Representative 1H-MR spectrum from the posterior cingulate cortex. Zero-filling to 8192 data
points and a 2-Hz Lorentzian filter were applied. PEth, Phosphoethanolamine; PCh, Phosphocholine; Pi, Inorganic phosphate; GPEth,
Glycerophosphoethanolamine; GPCh, Glycerophosphocholine; MP, Membrane phospholipids; PCr, Phosphocreatine; ATP, Adenosine triphosphate;
NAD(H), Nicotinamide adenine dinucleotide; ppm, Parts per million; NAA, N-acetyl-aspartate; tCho, Choline-containing compounds; tCr, Total creatine;
mI, Myo-inositol
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and its fit was assigned to the correct resonance, giving a
minimal residue, the fitting result was accepted.
The LCModel software package (version 6.3-0C [31])
was used for postprocessing (e.g., eddy current correction
and water scaling) and for automatic fitting of all 1H-MR
spectra (i.e., two hippocampal voxels, ACC and PCC). The
signal intensities of NAA, mI and glycine, and choline-
containing compounds (tCho: PCh, GPCh, and free cho-
line) were expressed relative to the intensity of creatine
and phosphocreatine (tCr). Additionally, water-referenced
levels of NAA, mI, tCho, and tCr, expressed in millimolar
tissue concentration, and the ratio of NAA to mI were cal-
culated. In the quantitative evaluation of the fitting results,
a whole spectrum was rejected when the full-width half-
maximum was >0.15 ppm (18.5 Hz) or the signal-to-noise
ratio was <5, and only individual metabolite fits with a
CRLB <30% were considered reliable. Qualitatively, two
spectroscopists (AR and MvdG) independently judged the
original spectra and the fitting results by visual inspection
according to a prespecified set of criteria.
T1-weighted MR images from one visit were segmented
into gray matter (GM), white matter (WM), and CSF
using automatic segmentation software (SPM8, Welcome
Trust Centre for Neuroimaging, London, UK; VBM8,
Structural Brain Mapping Group, Jena, Germany). For
each subject, the whole-brain GM fraction (GM/[GM+
WM+CSF]) was calculated and used as a prespecified
confounder in supportive covariate analyses.
Statistical analyses
All statistical analyses were performed for the modified
intention-to-treat (ITT) dataset, including all subjects who
received at least one unit of the study product and had at
least one MR measurement. The main statistical analyses of
the MRS outcome parameters were also performed for the
per-protocol (PP) population, which includes all subjects
who had no major protocol deviations. All blood outcome
parameters at week 4 were analyzed using analysis of covari-
ance (ANCOVA) with between-subjects factors intervention
group and sex, and with baseline measure as covariate.
All MRS outcome parameters at week 4 were analyzed
using a predefined multilevel model with intervention
group (test or control), sex, and brain region and its inter-
action with intervention group as fixed factors, considering
brain region as a within-subject factor and adjusting for
baseline. An unstructured variance-covariance matrix for
brain region was selected. If the p value for intervention
group by brain region interaction was <0.10, ANCOVA
models per brain region were used. If the p value for the
intervention by brain region interaction was >0.10, the
interaction term was dropped from the model. For all fitted
models, the influence diagnostics were used to explore the
influence of different observations on the models. Analyses
of the main 31P-MRS (PME, PDE, PME/PDE) and main
1H-MRS outcomes (NAA/tCr, mI/tCr, Cho/tCr, NAA/mI)
were performed on partially unblinded data (using inter-
vention group coded as X and Y), allowing analysis of the
intervention effect while keeping the statisticians blinded to
group allocation. The primary statistical analyses of these
main outcome parameters were repeated with adjustments
for possible confounders (i.e., MMSE, age, education level
[low, medium, high], GM fraction, and intake of choline-
containing food [only for choline-related outcome
parameters]).
Additionally, the following predefined supportive ana-
lyses were performed on the main 31P-MRS (PME, PDE,
PME/PDE) and main 1H-MRS (NAA/tCr, mI/tCr, Cho/
tCr, NAA/mI) outcome parameters. First, the primary
analyses described above were repeated using imputed
baseline values when baseline values were missing. Thus,
MRS outcome parameters at week 4 were analyzed using
a predefined multilevel model with intervention group
(test or control), sex, and brain region and its interaction
with intervention group as fixed factors, considering
brain region as a within-subject factor and adjusting for
baseline, where missing baseline values were replaced by
imputed baseline values (so-called multilevel model with
imputation). Imputation of the baseline value was per-
formed by a regression imputation using age, sex, and
brain region. Second, linear mixed model analyses were
conducted including the baseline value and the week 4
value of the outcome parameter in the outcome vector
and including intervention group, sex, time, brain re-
gion, and two-way and three-way interactions between
intervention group, brain region, and time as fixed fac-
tors, and a random intercept for time per subject. In this
supportive model (so-called mixed model with time), the
intervention effect is expressed by the interaction of
time by intervention group. Third, the primary analyses
were repeated for the one brain region for which most
data were available. For all fitted models, the influence
diagnostics were used to explore the influence of differ-
ent observations on the models.
Statistical analyses were performed by both AR and
ACY using SAS 9.2 and SAS 9.4 software, respectively
(SAS Institute Inc., Cary, NC, USA). Statistical signifi-
cance for the intervention effect was set at p < 0.05 with-
out correction for multiple testing.
Results
Subjects
Of the 40 subjects who were screened, 34 subjects were
included and randomized to receive either the test or
the control product. One subject dropped out of the
study without MR measurements and prior to product
dispensing, owing to unexpected claustrophobia, which
was an exclusion criterion for the present study as de-
scribed in the study protocol. Hence, 33 subjects were
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included in the modified ITT population. Major protocol
deviations were present for four subjects: no MR mea-
surements at week 4 (n = 2) or (suspected) double prod-
uct intake prior to week 4 measurements (n = 2). Hence,
29 subjects were included in the PP population (for a
flowchart, see Fig. 2). Subjects in the test (n = 16) and
control (n = 17) groups (modified ITT population) were
comparable with respect to baseline characteristics
(Table 2). The test group reported 80 medical conditions
in the medical history, as compared with 120 medical
conditions in the control group. Adherence to the study
product, according to diary entries, was high (>96%) and
equal in both groups.
Safety analysis and concomitant medication
In total, 27 adverse events (AEs) were reported, none of
which were serious AEs. The number of subjects with at
least one AE did not differ statistically between groups (test:
13 AEs in 8 subjects, control: 14 AEs in 7 subjects, p= 0.732
by Fisher’s exact test). A total of 15 of 33 subjects (45.5% of
the total study population) reported at least one AE. AEs
that were most often reported for both study groups con-
cerned gastrointestinal system disorders (i.e., abdominal
pain, diarrhea, dyspepsia, nausea, vomiting). The majority of
AEs were considered to be unrelated to the study product.
Seven AEs (five in the test group and two in the control
group) had a relationship to the study product (“possibly” or
“probably”), and were all of gastrointestinal nature (i.e., diar-
rhea, dyspepsia, nausea, vomiting). Regarding the use of
concomitant medication (other than AD medication), 62.5%
of subjects in the test group and 82.4% of the control group
used concomitant medication until the 4-week intervention
period. After the intervention period, 4 of 16 subjects in the
test group and 8 of 17 subjects in the control group started
AD medication (galantamine, memantine, or rivastigmine).
Nutritional blood markers
Levels of uridine, choline, and vitamin E in plasma, as
well as percentages of DHA, EPA, and total long-chain
Fig. 2 Flowchart of subjects in study. ITT, Intention to treat; PP, Per protocol
Table 2 Subject characteristics
Test (n = 16) Control (n = 17)
Age, years 74.7 (4.8) 72.7 (8.2)
Male sex, n (%) 7 (44%) 7 (41%)
MMSE score 23.0 (2.1) 23.2 (1.8)
Time since diagnosis, months 1.7 [0.4-15.3] 1.4 [0.2-10.2]
BMI, kg/m2 24.2 (3.8) 26.7 (3.3)
Educational level, n (%)
Low 6 (37.5%) 4 (23.5%)
Medium 8 (50.0%) 9 (52.9%)
High 2 (12.5%) 4 (23.5%)
Study product compliance 96.4% (4.8) 99.0% (1.6)
AD Alzheimer’s disease, BMI body mass index, MMSE Mini Mental
State Examination
Education level: low, primary education or lower; middle, junior vocational
training; high, senior vocational or academic training
Data are presented as mean (SD) or median [range] unless otherwise indicated
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polyunsaturated fatty acids in plasma and in total fatty
acids in erythrocyte membrane, were higher at week 4 in
the test group than in the control group (all p < 0.001).
Homocysteine levels were lower after 4 weeks of test
product compared with the control product (p = 0.006).
Docosapentaenoic acid in plasma or erythrocyte mem-
brane was not significantly different at week 4 between
the groups (p = 0.628 and p = 0.840, respectively). For
details, see Table 3.
MRS outcomes
Good-quality 31P-MR and 1H-MR spectra were obtained
from all ROIs (Fig. 1b and d). If no significant interac-
tions between intervention group and brain region were
observed in the statistical analyses, only main interven-
tion group effects are reported. Furthermore, the results
from the covariate analyses are reported only if the po-
tential confounders substantially changed the interven-
tion effect. Because the ITT and PP analyses yielded the
same findings, only the ITT analyses are reported.
Primary 31P-MRS outcomes
A significant intervention effect showing higher PME/
PDE at week 4 in the test group than in the control
group was found using the primary statistical analysis
approach (i.e., predefined multilevel model) (least
squares [LS] mean ± SEM test: 1.35 ± 0.06, control: 1.17
± 0.06, p = 0.005) (Fig. 3). Visual inspection of the data
and the results from the supportive model indicated that
PME/PDE increased over time in the test group and de-
creased over time in the control group (see Additional
file 1: Table S1, model 2).
No differences between groups were observed regarding
the levels of PME LS mean ± SEM at week 4 (test: 12.05 ±
0.19, control: 11.93 ± 0.19, p = 0.628) or regarding levels of
PDE (LS mean ± SEM at week 4, test: 9.79 ± 0.23, control:
9.89 ± 0.22, p = 0.702). For the results from the supportive
models, see Additional file 1: Table S1.
Other 31P-MRS outcomes
The PEth/GPEth ratio was higher in the test group than
in the control group (LS mean ± SEM test: 2.02 ± 0.09,
control: 1.80 ± 0.09, LS mean difference [95% CI] 0.22
[−0.04 to 0.48], p = 0.091) (Fig. 4). There were no signifi-
cant differences between groups regarding the PCh/GPCh
ratio; levels of PEth, PCh, GPEth, GPCh, PCr, Pi, ATP, or
nicotinamide adenine dinucleotide; or pH (all p > 0.05).
1H-MRS outcomes
Using the primary statistical analysis approach, a signifi-
cant interaction with brain region was found for tCho/
tCr, leading to analyses per brain region. These showed
that tCho/tCr at week 4 was higher in the test group
than in the control group in the ACC (LS mean ± SEM
test: 0.302 ± 0.015, control: 0.258 ± 0.016, p = 0.068) and
in the HR (LS mean ± SEM test: 0.287 ± 0.004, control:
0.264 ± 0.004, p = 0.003), but not in the HL and PCC
(both p > 0.05) (Fig. 5). For the results from the support-
ive models, see Additional file 1: Table S2.
For absolute levels of tCho, a significant intervention
effect indicated that levels of tCho were higher at week 4
in the test group than in the control group (LS mean ±
SEM test: 1.94 ± 0.05, control: 1.83 ± 0.05, p = 0.018; LS
mean difference [95% CI] 0.11 [0.02 to 0.20], p = 0.018).
Table 3 Intervention effect on nutritional blood markers and homocysteine
Blood outcome parameter Mean estimated value at week 4 Difference between
groups at week 4
p Value for
intervention effectTest (n = 16) Control (n = 17)
Fatty acids in the erythrocyte membrane
DHA, % 4.9 2.8 2.1 (1.84 to 2.30) <0.001
EPA, % 1.7 0.8 0.8 (0.69 to 0.98) <0.001
DPA, % 1.6 1.6 0.014 (−0.12 to 0.15) 0.840
LC-PUFA (DHA + EPA + DPA), % 8.2 5.3 2.9 (2.51 to 3.24) <0.001
Fatty acids in blood plasma
DHA, % 4.4 1.5 2.9 (2.59 to 3.12) <0.001
EPA, % 2.1 0.8 1.3 (1.10 to 1.51) <0.001
DPA, % 0.50 0.49 0.008 (−0.03 to 0.04) 0.628
LC-PUFA (DHA + EPA + DPA), % 7.0 2.8 4.2 (3.79 to 4.53) <0.001
Choline levels in blood plasma, μM 14.4 9.0 5.4 (3.39 to 7.47) <0.001
Vitamin E levels in blood plasma, μM 50.9 39.6 11.4 (6.77 to 15.96) <0.001
Homocysteine levels in blood plasma, μM 9.8 12.4 −2.6 (−4.31 to -0.82) 0.006
Uridine levels in blood plasma, μM 14.8 2.6 12.2 (7.24 to 17.11) <0.001
Abbreviations: DHA Docosahexaenoic acid, EPA Eicosapentaenoic acid, DPA Docosapentaenoic acid, LC-PUFA Long-chain polyunsaturated fatty acids
The 95% CI is presented in parentheses
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There were no significant differences between groups re-
garding relative (i.e., relative to tCr) or absolute (i.e.,
water-referenced) levels of NAA or mI on the ratio NAA/
mI or regarding absolute levels of tCre (all p > 0.05).
Discussion
In this study, we investigated whether the medical food
Souvenaid, containing nutritional precursors and cofactors
for phospholipid membrane formation (i.e., FC), influ-
enced brain phospholipid metabolism in mild AD. The
observed effects indicate that this specific multinutrient
combination not only raises circulating levels of phospho-
lipid precursors after 4 weeks but also affects the balance
between brain metabolites of phospholipid formation and
breakdown in patients with mild AD. In addition, levels of
tCho were higher after the intervention in comparison
with the control product, whereas metabolic measures of
neural integrity, gliosis, and energy metabolism were not
significantly affected.
There is strong ex vivo evidence that in the AD brain,
phospholipid content is decreased [3], phospholipid mem-
brane composition is altered [3, 32], and phospholipid
anabolic and catabolic processes are disturbed [7, 33], and
Fig. 3 LS means ± SEM of PME/PDE at week 4 in the test and control
groups. * p < 0.05. LS, Least squares; PME, Phosphomonoesters;
PDE, Phosphodiesters
Fig. 4 LS means ± SEM of PEth/GPEth at week 4 in the test and
control groups. † p < 0.10. LS, Least squares; PEth,
Phosphoethanolamine; GPEth, Glycerophosphoethanolamine
Fig. 5 LS means ± SEM of tCho/tCr at week 4 in the test and control
groups for four brain regions. * p < 0.05, † p < 0.10. LS, Least squares;
tCho, Total choline; tCr, Total creatine; ACC, Anterior cingulate cortex;
PCC, Posterior cingulate cortex; HR, Right hippocampus; HL,
Left hippocampus
Rijpma et al. Alzheimer's Research & Therapy  (2017) 9:51 Page 8 of 11
a tight link of these changes with synaptic loss and synap-
tic dysfunction is presumed [32, 34]. The dependence of
the unsaturated, low-affinity enzymes in the phospholipid
synthesis pathway on substrate availability offers the op-
portunity to support this process by providing those sub-
strates that are rate-limiting. Short-term supplementation
with this specific multinutrient combination increases
plasma and erythrocyte levels of nutritional precursors
and cofactors for phospholipid membrane formation in
patients with mild AD, which confirms and extends previ-
ous studies [27], and thus may alleviate preexisting nutri-
tional deficiencies [14]. Because several mechanisms have
been described that move key nutrients across the blood-
brain barrier [9], the nutrients in the present investigation,
or their metabolites, are expected to reach the brain. Ac-
cordingly, we observed a significantly increased PME/PDE
ratio, which is considered to reflect the ratio of phospho-
lipid anabolites over catabolites [22, 35], across four brain
regions with 4 weeks of daily use of this multinutrient
combination in mild AD. This indicates that the nutrients
exert their effect on the brain’s phospholipid metabolism,
in line with the hypothesized mode of action of this multi-
nutrient combination. The observed changes in phospho-
lipid metabolism may promote neuronal membrane
formation and may stimulate dendritic spine formation, as
was shown previously in animal studies [8, 9, 11]. The re-
modeling of phospholipid membranes in the brain will
probably continue with prolonged intake, and thus con-
tinuous intake is needed for long-term effects on synapse
formation. This may underlie the effects that this inter-
vention has on memory in patients with mild AD [19, 20].
Future research is needed to confirm this hypothesis, as
well as to investigate the actual impact of the changes in
phospholipid metabolism on changes in synaptic function,
functional connectivity and brain structural volumes in
AD pathology, or on AD progression. Imaging techniques
such as 18F-fluorodeoxyglucose positron emission tomog-
raphy and structural MRI are currently used in ongoing
randomized controlled trials to further explore whether
this multinutrient combination affects synaptic function
and structural brain volumes [36].
It was observed that the significantly increased PME/PDE
ratio was driven by both an increased PME/PDE ratio in
the active group and a decreased PME/PDE ratio in the
control group. The decreased PME/PDE ratio in the con-
trol group was not expected over the course of 4 weeks of
follow-up. The clinical significance of this decrease with re-
spect to disease progression is currently unclear.
Because the PME/PDE ratio changed significantly but
individual and total phosphomonoesters (PEth, PCh, and
PME) and phosphodiesters (GPEth, GPCh, and PDE) did
not, it cannot be established whether phospholipid forma-
tion was increased, breakdown was decreased, or both. In
addition, the literature is inconclusive on in vivo levels of
these metabolites in AD because increased, decreased, and
unaltered levels of PME and PDE have been observed in
comparison with cognitively normal controls [37–42].
However, the effect of this multinutrient combination on
brain phospholipid metabolism appears to be driven
mainly by the ethanolamine pathway because PEth/
GPEth, but not PCh/GPCh, showed a trend toward an in-
crease. This is in line with other studies that show that
oral phospholipid precursors (pyrimidines and choline) in
healthy populations [25, 26, 43] predominantly affect the
ethanolamine pathway. However, in the present study,
both relative and absolute tCho levels were higher at
follow-up in the group receiving the multinutrient inter-
vention than in the control group, indicating an effect on
phosphocholine metabolism as well. The tCho signal re-
flects the choline-containing compounds PCh, GPCh, and
free choline, and while both PCh and GPCh were mea-
sured separately with 31P-MRS, no increase was detected
in either one. This discrepancy may have arisen because
the measured 1H-MRS and 31P-MRS brain volumes dif-
fered, but supportive statistical models could not confirm
the significant alterations of tCho after a 4-week interven-
tion, warranting cautious interpretation. The analyses did
reveal that changes in tCho may not be anatomically uni-
form, because the most prominent effects were observed
in the ACC and HR. Because choline levels also increase
in plasma, it is important to rule out that the measured in-
crease in brain choline does not just reflect the vascular
component of the measured volume. Using the available
data, it was estimated that the change in plasma levels
would constitute only about 0.2% of the change observed
in brain choline, even when assuming that all plasma cho-
line is MR-visible and estimating the vascular contribution
at a liberal 5%.
Reduced levels of NAA and increased levels of mI have
been shown consistently in AD [44], and it might have
been expected that this multinutrient combination
would decelerate the changes in these measures of
neural integrity and gliosis. Although uridine and DHA
were found to stimulate neurite outgrowth [45, 46], and
DHA is known to have anti-inflammatory effects in
addition to its role in the phospholipid synthesis path-
way [47], no group differences after 4 weeks of interven-
tion were observed regarding relative or absolute levels
of NAA or mI, nor were differences observed regarding
the NAA/mI ratio. However, the normal rate of change
over 4 weeks’ time may be limited, such that a deceler-
ation effect of the intervention is not yet discernible. Al-
though 4 weeks of intervention did affect phospholipid
metabolism, this period may have been too short to ob-
serve an effect on metabolic measures of neural integrity
and gliosis. Alternatively, it may be that the damage that
these metabolites reflect is already irreversible at this
stage of the disease.
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The findings of this study may be limited by the modest
sample size. Although there was sufficient power to detect
an effect on the PME/PDE ratio, one of the main outcome
measures, it was not possible to ascribe the increase in
this ratio to increased PME or decreased PDE. Moreover,
MR spectra were not always available or of sufficient qual-
ity from all investigated brain regions. Finally, a longer
intervention duration may have led to more robust find-
ings and more pronounced secondary outcomes.
Conclusions
This exploratory, double-blind, randomized controlled study
shows that the medical food Souvenaid affects phospholipid
metabolism across multiple brain regions in mild AD after
only 4 weeks. This could lead to increased neuronal mem-
brane formation, which would support the hypothesized
mode of action of this multinutrient intervention. Larger and
longer randomized controlled trials are needed to determine
long-term effects on phospholipid formation, synaptic func-
tion, and cognition in persons with and at risk for AD.
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